NO20092019L - Behandling av gjennomtrengende utviklingsforstyrrelser - Google Patents

Behandling av gjennomtrengende utviklingsforstyrrelser

Info

Publication number
NO20092019L
NO20092019L NO20092019A NO20092019A NO20092019L NO 20092019 L NO20092019 L NO 20092019L NO 20092019 A NO20092019 A NO 20092019A NO 20092019 A NO20092019 A NO 20092019A NO 20092019 L NO20092019 L NO 20092019L
Authority
NO
Norway
Prior art keywords
disorder
developmental disorders
pervasive developmental
treatment
pdds
Prior art date
Application number
NO20092019A
Other languages
English (en)
Inventor
Magali Haas
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20092019L publication Critical patent/NO20092019L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse er en fremgangsmåte for behandling av pervasive utviklingsforstyrrelser (PDD'er) som inkluderer; autistisk forstyrrelse, Aspergers syndrom, barnedisintegrativ forstyrrelse (CDD), Rett's forstyrrelse og PDD-ikke ellers spesifisert (PPD-NOS) som innbefatter administrering til et subjekt som trenger det en teapeutisk effektiv mengde av en eller flere karbamatforbindelser med formel 1 og/eller formel 2 som definert heri og vist nedenfor. Foreliggende oppfinnelse angår en fremgangsmåte for behandling av pervasive utviklingsforstyrrelser (PDD'er) som inkluderer; autistisk forstyrrelse, Aspergers syndrom, barnedisintegrativ forstyrrelse (CDD), Rett's forstyrrelse og PDD-ikke ellers spesifisert (PPD-NOS), som inkluderer monoterapi og alternativ, kombinasjonsterapi med minst en ytterligere psykoaktiv medisinering.
NO20092019A 2006-10-31 2009-05-25 Behandling av gjennomtrengende utviklingsforstyrrelser NO20092019L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86359506P 2006-10-31 2006-10-31
PCT/US2007/081365 WO2008054984A1 (en) 2006-10-31 2007-10-15 Treatment of pervasive developmental disorders

Publications (1)

Publication Number Publication Date
NO20092019L true NO20092019L (no) 2009-06-23

Family

ID=39145417

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092019A NO20092019L (no) 2006-10-31 2009-05-25 Behandling av gjennomtrengende utviklingsforstyrrelser

Country Status (17)

Country Link
US (1) US20080103199A1 (no)
EP (1) EP2089011A1 (no)
JP (1) JP2010508354A (no)
KR (1) KR20090080105A (no)
CN (1) CN101568333A (no)
AU (1) AU2007313911A1 (no)
BR (1) BRPI0718323A2 (no)
CA (1) CA2667909A1 (no)
CO (1) CO6180427A2 (no)
EA (1) EA200970435A1 (no)
GT (1) GT200900112A (no)
IL (1) IL198488A0 (no)
MX (1) MX2009004798A (no)
NI (1) NI200900074A (no)
NO (1) NO20092019L (no)
WO (1) WO2008054984A1 (no)
ZA (1) ZA200903772B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
WO2010020585A1 (en) * 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
WO2012018387A2 (en) 2010-08-02 2012-02-09 Population Diagnotics, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
EP2766483B1 (en) 2011-10-10 2022-03-23 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
EP2773779B1 (en) 2011-11-04 2020-10-14 Population Bio, Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
US10407724B2 (en) 2012-02-09 2019-09-10 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
HK1211239A1 (en) * 2012-08-06 2016-05-20 S1 Biopharma, Inc. Treatment regimens
DK2895621T3 (da) 2012-09-14 2020-11-30 Population Bio Inc Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
WO2014052855A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
US9566261B2 (en) * 2013-03-12 2017-02-14 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a memory loss-related disease comprising the same
GB2558326B (en) 2014-09-05 2021-01-20 Population Bio Inc Methods and compositions for inhibiting and treating neurological conditions
KR102635938B1 (ko) * 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP4177356B1 (en) 2018-08-08 2024-05-08 PML Screening, LLC Methods for assessing risk of developing a viral disease using a genetic test
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03007717A (es) * 2001-02-27 2005-11-08 Johnson & Johnson Compuestos de carbamato para su uso en la prevencion o tratamiento de trastornos bipolares.
CN1262272C (zh) * 2001-02-27 2006-07-05 奥索-麦克尼尔药品公司 用于预防或治疗运动障碍的氨基甲酸酯化合物
US6541513B2 (en) * 2001-02-27 2003-04-01 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating psychotic disorders
PL364680A1 (en) * 2001-02-27 2004-12-13 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating neurodegenerative disorders
CA2580640A1 (en) * 2004-09-16 2006-03-30 Janssen Pharmaceutica N.V. Methods of treating epileptogensis and epilepsy

Also Published As

Publication number Publication date
US20080103199A1 (en) 2008-05-01
CN101568333A (zh) 2009-10-28
WO2008054984A1 (en) 2008-05-08
IL198488A0 (en) 2010-02-17
AU2007313911A1 (en) 2008-05-08
JP2010508354A (ja) 2010-03-18
EA200970435A1 (ru) 2009-10-30
BRPI0718323A2 (pt) 2013-11-26
CO6180427A2 (es) 2010-07-19
NI200900074A (es) 2010-02-01
GT200900112A (es) 2010-05-18
KR20090080105A (ko) 2009-07-23
EP2089011A1 (en) 2009-08-19
MX2009004798A (es) 2009-08-12
CA2667909A1 (en) 2008-05-08
ZA200903772B (en) 2010-08-25

Similar Documents

Publication Publication Date Title
NO20092019L (no) Behandling av gjennomtrengende utviklingsforstyrrelser
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EA201391670A1 (ru) 1,3-оксазины в качестве ингибиторов bace1 и/или bace2
BR112013031510A2 (pt) [1,3]oxazinas
TW200638934A (en) Heteroaryl compounds as P2Y1 receptor inhibitors
CL2012003401A1 (es) Compuestos derivados de carbamato de hexafluoroisopropilo, inhibidores de la enzima monoacil glicerol lipasa (mgl); proceso de preparacion; medicamento; compuestos intermediarios; composicion farmaceutica; y su uso para tratar o prevenir dolores agudos o cronicos, vertigos, dislipidemias y epilepsia, entre otras enfermedades.
NO20084931L (no) Farmasoytiske sammensetninger
EA201391752A1 (ru) Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201200054A1 (ru) Лечение токотриенолами или экстрактами, богатыми токотриенолами, первазивных расстройств развития
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
DOP2006000170A (es) Nuevos derivados de espirocromanona
EA201200406A1 (ru) Соединения и композиции, которые являются модуляторами активности tlr
EA200800564A1 (ru) Производные ксантина как селективные агонисты нм74а
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application